The environment
The cost of capital has re-rated valuations, and buyers are underwriting more conservatively. Strategic acquirers and disciplined sponsors remain active, but the bar for reimbursement durability has risen. Antitrust attention on provider concentration adds a second filter, particularly for platforms with high local share in a specialty.
In this market, the reimbursement diligence is the deal. A target with a great growth story and fragile rates is a worse asset than a slower grower with durable, well-contracted reimbursement.
What's driving — and constraining — deals
- Reimbursement durability. Buyers scrutinize rate sustainability, payer mix, and Medicare linkage more than headline growth.
- No Surprises Act. Targets that relied on out-of-network economics are repriced down; in-network durability is prized.
- Antitrust. Concentration invites review and can reshape or block transactions.
- Site-neutral and transparency. Policy exposure is now a standard diligence line item.
A reimbursement lens on value
| Diligence area | Question | Why it matters |
|---|---|---|
| Rate durability | How linked to Medicare? Fixed or floating? | Silent cuts flow through floating rates |
| Payer mix | Concentration and MA exposure | Denial and yield risk |
| NSA / QPA | Out-of-network reliance? | Post-NSA repricing risk |
| Policy exposure | Site-neutral, transparency | Future margin risk |
Illustrative; scope by sector and target.
Positioning for a transaction
Sellers who prepare reimbursement — clean contracts, documented rate rationale, quantified policy exposure, and a credible in-network story — transact at better multiples and with fewer surprises. Buyers who diligence reimbursement rigorously avoid paying growth multiples for fragile rates. Either way, the reimbursement work is where value is protected.